- Home
- JYD vs ALXO Comparison
JYD vs ALXO Comparison
Compare JYD & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- ALXO
- Stock Information
- Founded
- JYD 2001
- ALXO 2015
- Country
- JYD China
- ALXO United States
- Employees
- JYD N/A
- ALXO N/A
- Industry
- JYD Oil Refining/Marketing
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- ALXO Health Care
- Exchange
- JYD Nasdaq
- ALXO Nasdaq
- Market Cap
- JYD 23.3M
- ALXO 24.0M
- IPO Year
- JYD 2023
- ALXO 2020
- Fundamental
- Price
- JYD $0.18
- ALXO $0.48
- Analyst Decision
- JYD
- ALXO Strong Buy
- Analyst Count
- JYD 0
- ALXO 6
- Target Price
- JYD N/A
- ALXO $3.30
- AVG Volume (30 Days)
- JYD 2.3M
- ALXO 397.6K
- Earning Date
- JYD 07-01-2025
- ALXO 08-07-2025
- Dividend Yield
- JYD N/A
- ALXO N/A
- EPS Growth
- JYD N/A
- ALXO N/A
- EPS
- JYD N/A
- ALXO N/A
- Revenue
- JYD $77,444,271.00
- ALXO N/A
- Revenue This Year
- JYD N/A
- ALXO N/A
- Revenue Next Year
- JYD N/A
- ALXO N/A
- P/E Ratio
- JYD N/A
- ALXO N/A
- Revenue Growth
- JYD 13.54
- ALXO N/A
- 52 Week Low
- JYD $0.09
- ALXO $0.41
- 52 Week High
- JYD $8.00
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- JYD 32.88
- ALXO 44.63
- Support Level
- JYD $0.19
- ALXO $0.48
- Resistance Level
- JYD $0.21
- ALXO $0.59
- Average True Range (ATR)
- JYD 0.01
- ALXO 0.05
- MACD
- JYD 0.03
- ALXO -0.00
- Stochastic Oscillator
- JYD 0.00
- ALXO 8.75
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is a end-to-end supply chain solution providers in China, with a focus on providing cross-border logistics services. It offers freight forwarding services, (ii) supply chain management, and (iii) other value-added services.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.